行情

ENTA

ENTA

Enanta制药
NASDAQ

实时行情|Nasdaq Last Sale

61.77
-1.74
-2.74%
盘后: 61.77 0 0.00% 16:00 11/11 EST
开盘
63.35
昨收
63.51
最高
63.72
最低
61.57
成交量
8.57万
成交额
--
52周最高
106.80
52周最低
57.15
市值
12.16亿
市盈率(TTM)
20.05
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ENTA 新闻

  • 智能眼镜成新风口?盘点美国七家制造商的AR设备
  • 新浪美股.2小时前
  • 收盘:美股涨跌不一 波音推动道指创新高
  • 新浪美股.2小时前
  • 美国原油期货价格周一收跌0.7%
  • 新浪美股.3小时前
  • 尾盘:美股涨跌不一 波音推动道指转涨
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
-0.51%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

ENTA 简况

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
展开

Webull提供Enanta Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。